Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510913 · ClinicalTrials.gov registry record · Phase 4
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 450
- Enrollment target
NCT00510913 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 450 participants.
The verdict
NCT00510913, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 450 participants
- Enrollment target
Study Summary
A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
Interventions
- DRUG tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 1999-02 |
| Est. Completion | 2000-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510913
The ClinicalTrials.gov registry entry for NCT00510913 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tacrolimus is the first listed.
NCT00510913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510913 about?
NCT00510913 is a clinical study titled "A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure". A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
What is the current status of trial NCT00510913?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 450 participants. The study started on 1999-02. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00510913?
The interventions under investigation include: tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00510913?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.